EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis

Junna Yamaguchi, Pierre Isnard, Noémie Robil, Pierre de la Grange, Clément Hoguin, Alain Schmitt, Aurélie Hummel, Jérôme Megret, Nicolas Goudin, Marine Luka, Mickaël M Ménager, Cécile Masson und 11 weitere

Journal of Clinical Investigation · 01.08.2024 · 134 (15)

DOI: 10.1172/jci176402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 06.06.2024. Verfasst von Junna Yamaguchi und 22 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Disease Models, Animal, Lupus Nephritis, Podocytes. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Agence Nationale de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proliferative glomerulonephritis is a severe condition that often leads to kidney failure. There is a significant lack of effective treatment for these disorders. Here, following the identification of a somatic PIK3CA gain-of-function mutation in podocytes of a patient, we demonstrate using multiple genetically engineered mouse models, single-cell RNA sequencing, and spatial transcriptomics the crucial role played by this pathway for proliferative glomerulonephritis development by promoting podocyte proliferation, dedifferentiation, and inflammation. Additionally, we show that alpelisib, a PI3Kα inhibitor, improves glomerular lesions and kidney function in different mouse models of proliferative glomerulonephritis and lupus nephritis by targeting podocytes. Surprisingly, we determined that pharmacological inhibition of PI3Kα affects B and T lymphocyte populations in lupus nephritis mouse models, with a decrease in the production of proinflammatory cytokines, autoantibodies, and glomerular complement deposition, which are all characteristic features of PI3Kδ inhibition, the primary PI3K isoform expressed in lymphocytes. Importantly, PI3Kα inhibition does not impact lymphocyte function under normal conditions. These findings were then confirmed in human lymphocytes isolated from patients with active lupus nephritis. In conclusion, we demonstrate the major role played by PI3Kα in proliferative glomerulonephritis and show that in this condition, alpelisib acts on both podocytes and the immune system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Class I Phosphatidylinositol 3-KinasesDisease Models, AnimalLupus NephritisPodocytesAnimalsFemaleHumansMiceB-LymphocytesGlomerulonephritisPhosphoinositide-3 Kinase InhibitorsT-LymphocytesThiazoles

Stichwörter der Autor:innen

Molecular biologyNephrology

Substanzen

AlpelisibClass I Phosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPIK3CA protein, humanThiazolesPik3ca protein, mouse

Autor:innen und Institutionen

  • Université Paris Cité, Paris, France.
  • Unité de Médecine Translationnelle et Thérapies Ciblées, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
  • INSERM U1151, Institut Necker-Enfants Malades, Paris, France.
  • Service d'Anatomie pathologique, Hôpital Necker-Enfants Malades, AP-HP, Paris, France.
  • Genosplice Technology, Paris Biotech Santé, Paris, France.
  • Institut Cochin, Paris, France.

Förderung

  • European Research Council
  • Agence Nationale de la Recherche

Zitieren

APA

Yamaguchi, J., Isnard, P., Robil, N., de la Grange, P., Hoguin, C., Schmitt, A., Hummel, A., Megret, J., Goudin, N., Luka, M., Ménager, M. M., Masson, C., Zarhrate, M., Bôle-Feysot, C., Janiszewska, M., Polyak, K., Dairou, J., Baldassari, S., Baulac, S., …, & Canaud, G. (2024). PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis. Journal of Clinical Investigation, 134(15). https://doi.org/10.1172/jci176402

Vancouver

Yamaguchi J, Isnard P, Robil N, de la Grange P, Hoguin C, Schmitt A, et al. PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis. Journal of Clinical Investigation. 2024;134(15). doi:10.1172/jci176402

BibTeX
@article{Yamaguchi2024,
  author = {Yamaguchi, Junna and Isnard, Pierre and Robil, Noémie and de la Grange, Pierre and Hoguin, Clément and Schmitt, Alain and Hummel, Aurélie and Megret, Jérôme and Goudin, Nicolas and Luka, Marine and Ménager, Mickaël M and Masson, Cécile and Zarhrate, Mohammed and Bôle-Feysot, Christine and Janiszewska, Michalina and Polyak, Kornelia and Dairou, Julien and Baldassari, Sara and Baulac, Stéphanie and Broissand, Christine and Legendre, Christophe and Terzi, Fabiola and Canaud, Guillaume},
  title = {PIK3CA inhibition in models of proliferative glomerulonephritis and lupus nephritis},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {15},
  doi = {10.1172/jci176402}
}
Kostenlos starten →